ClinicaliQ Trial Snapshot
- Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis — Recruiting • Phase II • Gastroenterology • NCT07332091.
- Vamifeport reduced liver iron levels in adults with hereditary hemochromatosis, a genetic iron overload disorder.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH. Conditions: Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis Interventions: Vamifeport, Placebo Lead Sponsor: CSL Behring Planned Enrollment: 84 participants